Randomized trial evaluating self-sampling for HPV DNA based tests for cervical cancer screening in Nigeria
Open Access
- 6 February 2017
- journal article
- research article
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 12 (1) , 1-9
Abstract
Cervical cancer incidence and mortality rates in Sub-Saharan Africa (SSA) remain high due to several factors including low levels of uptake of cervical cancer screening. Self-collection of cervicovaginal samples for HPV DNA testing may be an effective modality that can increase uptake of cervical cancer screening in SSA and hard to reach populations in developed countries. We investigated whether self-collection of cervicovaginal samples for HPV DNA tests would be associated with increased uptake of screening compared with clinic based collection of samples. Furthermore, we compared the quality of samples collected by both approaches for use in HPV genotyping. We conducted a community based randomized trial in a semi-urban district of Abuja, Nigeria with 400 women, aged 30 to 65 years randomized to either hospital-collection or self-collection of cervicovaginal samples. We compared cervical cancer screening uptake among the 2 groups and evaluated the concentration of human DNA in the samples by measuring RNase P gene levels using qPCR. High-risk HPV DNA detection and typing was done using the GP5+/6+ Luminex system. Most participants in the self-collection arm (93%, 185/200) submitted their samples while only 56% (113/200) of those invited to the hospital for sample collection attended and were screened during the study period (p value < 0.001). Human genomic DNA was detected in all but five (1.7%) participants, all of whom were in the self-collection arm. The prevalence of high-risk HPV in the study population was 10% with types 35, 52 and 18 being the commonest. Our study shows that self-sampling significantly increased uptake of HPV DNA based test for cervical cancer screening in this population and the samples collected were adequate for HPV detection and genotyping. Cervical cancer screening programs that incorporate self-sampling and HPV DNA tests are feasible and may significantly improve uptake of cervical cancer screening in SSA.Keywords
Funding Information
- National Human Genome Research Institute (NIH/NHGRI U54HG006947)
- National Institutes of Health (1D43CA153792)
This publication has 35 references indexed in Scilit:
- HIV associated high-risk HPV infection among Nigerian womenBMC Infectious Diseases, 2013
- Cervical cancer risk factors among HIV-infected Nigerian womenBMC Public Health, 2013
- Dry Storage and Transport of a Cervicovaginal Self-Sample by Use of the Evalyn Brush, Providing Reliable Human Papillomavirus Detection Combined with Comfort for WomenJournal of Clinical Microbiology, 2012
- The age‐specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: Implications for screen‐and‐treat strategiesInternational Journal of Cancer, 2011
- Cervical Human Papillomavirus Prevalence in 5 Continents: Meta‐Analysis of 1 Million Women with Normal Cytological FindingsThe Journal of Infectious Diseases, 2010
- HPV infection in women with and without cervical cancer in Conakry, GuineaBritish Journal of Cancer, 2009
- HPV Screening for Cervical Cancer in Rural IndiaNew England Journal of Medicine, 2009
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Overview of Human Papillomavirus-Based and Other Novel Options for Cervical Cancer Screening in Developed and Developing CountriesVaccine, 2008
- Cost-Effectiveness of Cervical Cancer Screening With Human Papillomavirus DNA Testing and HPV-16,18 VaccinationJNCI: Journal of the National Cancer Institute, 2008